REGULATORY
Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
A Japanese health ministry panel will meet on December 2 to review Eli Lilly’s once-daily obesity drug orforglipron, known as Foundayo overseas, which would become Japan’s first oral GLP-1 receptor agonist for the condition if…

LATEST

November 19, 2026
Tanabe Pharma said on November 19 that it will wind down operations at its wholly owned Israeli subsidiary NeuroDerm as it shifts resources toward its domestic business, jettisoning plans to commercialize its Parkinson’s therapy Onerji…
November 19, 2026
The ruling Liberal Democratic Party’s (LDP) project team on pharmaceutical innovation plans to draft policy recommendations next week following its November 19 hearing where major trade groups pushed back against the proposed expansion of the…
November 19, 2026
Japan is poised to approve its first biosimilars of Daiichi Sankyo’s osteoporosis drug Pralia (denosumab), with five products waiting in the wings for simultaneous green lights in December and a potential listing next May, if…
By Shunsuke Tani

Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…

Japan’s health ministry on November 16 approved AbbVie’s glabellar lines drug Boey (trenibotulinumtoxinE), along with a slate of label expansions…

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA